MedTrace Logo

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NCT03564197 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-27

No results posted yet for this study

Summary

A multicenter single arm biomarker exploration and validation study. Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line and beyond PD-(L)1 immunotherapy monotherapy according to EMA label and national guidelines will be enrolled in this trial. All subjects will undergo a whole body 18F-PD-L1 PET/CT scan before start of nivolumab containing treatment. Patients will continue treatment until disease progression, withdrawal of patient consent or unacceptable toxicity.

Conditions

  • NSCLC Stage IV

Interventions

OTHER

18F-PD-L1

18F-PD-L1 PET/CT scan

Sponsors & Collaborators

Principal Investigators

  • Joop de Langen, MD · The Netherlands Cancer Institute-Antoni van Leeuwenhoek

  • Egbert Smit, MD · The Netherlands Cancer Institute-Antoni van Leeuwenhoek

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-25
Primary Completion
2025-01-30
Completion
2026-01-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03564197 on ClinicalTrials.gov